Abstract
In the last decade, several neoadjuvant trials for NSCLC. patients with mediastinal lymph node involvement (N2) have been scheduled. The uniform plan is based on clinical staging, therapy clinical re-staging, surgery (when is possible) and, finally, pathological staging The precise classification of tumor during the' three different staging procedures is mandatory. Considering clinical re-staging and pathological staqinq, nowadays surgery could be considered correct for most of the patients enrolled in the neoadjuvant protocols including cases where a major clinical response has not been achieved. Several experiences demonstrated how often the clinical re-staging overesteems neoplastic tissue by fibrosis and scar and could judge as unserectablc patients with a minimal residual disease.
Original language | English |
---|---|
Pages (from-to) | 899-903 |
Number of pages | 5 |
Journal | Annali Italiani di Chirurgia |
Volume | 70 |
Issue number | 6 |
Publication status | Published - Nov 1999 |
Keywords
- Lung cancer
- N2 patients
- Neoadjuvant therapy
- Re-staging
- Staging
ASJC Scopus subject areas
- Surgery